Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07565064Enrolling By Invitation

ALPCO 25(OH) Vitamin D CLIA Kit - Fresh Versus Frozen Serum and Plasma Stability Study

Role: lead

NCT07089420Completed

ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects

Role: lead

NCT06810518Recruiting

ALPCO Calprotectin CLIA Assay - Measurement of Calprotectin Levels in Human Stool

Role: lead

NCT07089836Recruiting

This Study Evaluates the ALPCO Syphilis-T and Syphilis-NT CLIA Kits for Detecting Syphilis Antibodies in Serum and Plasma. Samples From At-risk, HIV-positive, Pregnant, and Healthy Individuals Will Assess Assay Performance Versus Established Comparator Tests.

Role: lead

NCT03082287Completed

ALPCO Calprotectin ELISA - Measurement of Calprotectin Levels in Human Stool

Role: lead

All 5 trials loaded